Zobrazeno 1 - 6
of 6
pro vyhledávání: '"R L, Ho"'
Autor:
C. A. Lieu, R L Ho
Publikováno v:
Drugs in RD. 9(4)
Investments in systems biology approaches by the pharmaceutical industry have not yet yielded the payoffs envisaged by many. In most cases, a plethora of novel drug targets arising from genomics led to many more failed projects in the pipeline, sugge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::892f2b1472c55ea8c23e97db2f007262
https://pubmed.ncbi.nlm.nih.gov/18588352
https://pubmed.ncbi.nlm.nih.gov/18588352
Publikováno v:
Oncology research. 6(4-5)
Recently we have reported the development of a safe and effective chemoimmunotherapy protocol involving doxorubicin (Dox) in combination with interleukin 2 which, in C57BL/6 mice, boosts local T cell responses, and, in 50 to 80% of the cases, this re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f76f08d368f462100c8b64cb2b269095
https://pubmed.ncbi.nlm.nih.gov/7841541
https://pubmed.ncbi.nlm.nih.gov/7841541
Publikováno v:
Oncology research. 5(9)
A safe and effective therapeutic combination of moderate doses of Adriamycin (doxorubicin, 4 mg/kg, IV, Days 1 and 8 or only Day 8) plus prolonged administration of moderate doses of interleukin 2 (2 micrograms, b.i.d., Days 9-40) was developed in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::30ef32f97c115ea46746a512a7a7d8b2
https://pubmed.ncbi.nlm.nih.gov/8038457
https://pubmed.ncbi.nlm.nih.gov/8038457
Publikováno v:
Oncology research. 5(9)
This laboratory has extensively studied Adriamycin (doxorubicin)-induced immunomodulation. Despite demonstration of favorable effects, little therapeutic advantage was seen, and it was decided to test Adriamycin in combination with interleukin 2 (IL2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2b97184c446d7451d131f0b4657ae6d2
https://pubmed.ncbi.nlm.nih.gov/8038458
https://pubmed.ncbi.nlm.nih.gov/8038458
Publikováno v:
Cancer communications. 2(5)
A number of recent studies have implied that a relationship exists between cellular sensitivities to tumor necrosis factor (TNF) and expression of the classic multidrug resistance (MDR) phenotype. However, different conclusions have been reported con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4017c9f0c7aec67d89ebf8fe03388962
https://pubmed.ncbi.nlm.nih.gov/1973358
https://pubmed.ncbi.nlm.nih.gov/1973358
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.